Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease

Hadley Derrin Bortz, John Coutsouvelis, Carmela Corallo, Andrew Spencer, Sushrut Patil

Research output: Contribution to journalArticleOther


What is known and objective Intensive chemotherapy for treatment of Burkitt s lymphoma (BL) - a high-grade lymphoproliferative disorder (LPD) - can cause neurotoxicity. An association between motor neurone disease (MND) and LPDs has previously been described, but there is a lack of recommendations available to guide management of such patients. This report aims to describe suitable management of BL in a patient with MND. Case description A 66-year-old woman with a history of MND affecting her limbs was diagnosed with bulky, extranodal, high-risk gastric BL. Standard chemotherapy is with multiple non-cross-resistant cytotoxic agents. To avoid exacerbation of neuropathy, six cycles of a modified regimen was planned, aiming to minimize exposure to the most neurotoxic agents. A PET-FDG-negative remission was obtained at 12 months, without the signs of central neurotoxicity, peripheral neuropathy or muscle weakness. What is new and conclusion High-intensity chemotherapy, minimizing known neurotoxic agents, was delivered safely and effectively in a patient with BL and pre-existing MND. More case descriptions are required to guide management decisions. This report describes a modified high-intensity chemotherapy regimen designed to minimize neurotoxicity, which was used successfully in the treatment of burkitt s lymphoma in a patient with motor neurone disease, adding to limited information in the literature.
Original languageEnglish
Pages (from-to)483 - 485
Number of pages3
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number4
Publication statusPublished - 2015

Cite this